The gut-to-breast connection - interdependence of sterols and sphingolipids in multidrug resistance and breast cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 882-890

  Spassieva, Stefka ^a   Bieberich, Erhard ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Apoptosis; Bile acids; Ceramide; Cholesterol; Deoxycholate; FXR; Glucosylceramide; Lipd rafts; Multidrug resistance; Sphingomyelin

Indexed keywords

ANTIMETASTATIC AGENT; BILE ACID; CHOLESTEROL; CHOLESTEROL DERIVATIVE; CYCLOPHOSPHAMIDE; DEOXYCHOLIC ACID; DOFEQUIDAR; DOXORUBICIN; FARNESOID X RECEPTOR; FLUOROURACIL; GLUCOSYLCERAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSANOID; LYSOPHOSPHOLIPID; MEMBRANE PROTEIN; PHOSPHOLIPID; SPHINGOLIPID; SPHINGOMYELIN; STEROL DERIVATIVE; UNCLASSIFIED DRUG; Z GUGGUSTERONE;

BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL SURVIVAL; HUMAN; INTESTINE FLORA; LIPID METABOLISM; LIPID RAFT; MEMBRANE STRUCTURE; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 80054072283     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797655168     Document Type: Review

References (127)

1. Ogretmen, B.; Hannun, Y.A., Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer, 2004, 4, (8), 604-616.
2. Ponnusamy, S.; Meyers-Needham, M.; Senkal, C.E.; Saddoughi, S.A.; Sentelle, D.; Selvam, S.P.; Salas, A.; Ogretmen, B., Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol., 2010, 6, (10), 1603-1624.
3. Pruett, S.T.; Bushnev, A.; Hagedorn, K.; Adiga, M.; Haynes, C.A.; Sullards, M.C.; Liotta, D.C.; Merrill, A.H., Jr., Biodiversity of sphingoid bases (sphingosines) and related amino alcohols. J. Lipid Res., 2008, 49, (8), 1621-1639.
4. Bieberich, E., Ceramide signaling in cancer and stem cells. Future Lipidol, 2008, 3, (3), 273-300.
5. Bieberich, E., Integration of glycosphingolipid metabolism and cell-fate decisions in cancer and stem cells: review and hypothesis. Glycoconj. J., 2004, 21, (6), 315-327.
6. Alemany, R.; van Koppen, C.J.; Danneberg, K.; Ter Braak, M.; Meyer Zu Heringdorf, D., Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol, 2007.
7. Zeidan, Y.H.; Jenkins, R.W.; Hannun, Y.A., Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J. Cell Biol., 2008, 181, (2), 335-350.
8. Goetzl, E.J.; Graeler, M.; Huang, M.C.; Shankar, G., Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer. ScientificWorldJournal, 2002, 2, 324-338.
9. Meyer zu Heringdorf, D.; Jakobs, K.H., Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta, 2007, 1768, (4), 923-940.
10. Smicun, Y.; Gil, O.; Devine, K.; Fishman, D.A., S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells. Gynecol.Oncol., 2007, 107, (2), 298-309.
11. Takabe, K.; Paugh, S.W.; Milstien, S.; Spiegel, S., Inside-out signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev., 2008, 60, (2), 181-195.
12. Lebman, D.A.; Spiegel, S., Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling. J Lipid Res, 2008, 49, (7), 1388-1394.
13. Skoura, A.; Hla, T., Lysophospholipid receptors in vertebrate development, physiology, and pathology. J. Lipid Res., 2009, 50 Suppl, S293-298.
14. Storch, C.H.; Ehehalt, R.; Haefeli, W.E.; Weiss, J., Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp.Ther., 2007, 323, (1), 257-264.
15. Dumitru, C.A.; Weller, M.; Gulbins, E., Ceramide metabolism determines glioma cell resistance to chemotherapy. J. Cell Physiol., 2009, 221, (3), 688-695.
16. Lavie, Y.; Fiucci, G.; Czarny, M.; Liscovitch, M., Changes in membrane microdomains and caveolae constituents in multidrugresistant cancer cells. Lipids, 1999, 34 Suppl, S57-63.
17. Lavie, Y.; Liscovitch, M., Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycocon. J., 2000, 17, (3 -4), 253-259.
18. Meacham, W.D.; Antoon, J.W.; Burow, M.E.; Struckhoff, A.P.; Beckman, B.S., Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp. Biol. Med. (Maywood), 2009, 234, (11), 1253-1263.
19. Fyrst, H.; Saba, J.D., An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol, 2010, 6, (7), 489-497.
20. Snook, C.F.; Jones, J.A.; Hannun, Y.A., Sphingolipid-binding proteins. Biochim. Biophys. Acta, 2006, 1761, (8), 927-946.
21. Herzog, M.; Storch, C.H.; Gut, P.; Kotlyar, D.; Fullekrug, J.; Ehehalt, R.; Haefeli, W.E.; Weiss, J., Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn. Schmiedebergs Arch. Pharmacol., 2011, 383, (1), 1-11.
22. Gulbins, E.; Kolesnick, R., Raft ceramide in molecular medicine. Oncogene, 2003, 22, (45), 7070-7077.
23. Gulbins, E.; Grassme, H., Ceramide and cell death receptor clustering. Biochim. Biophys. Acta, 2002, 1585, (2-3), 139-145.
24. Hait, N.C.; Allegood, J.; Maceyka, M.; Strub, G.M.; Harikumar, K.B.; Singh, S.K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; Spiegel, S., Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 2009, 325, (5945), 1254-1257.
25. Chalfant, C.E.; Spiegel, S., Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci, 2005, 118, (Pt 20), 4605-4612.
26. Bhola, N.E.; Grandis, J.R., Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci., 2008, 13, 1857-1865.
27. Debruyne, P.R.; Bruyneel, E.A.; Li, X.; Zimber, A.; Gespach, C.; Mareel, M.M., The role of bile acids in carcinogenesis. Mutat. Res., 2001, 480-481, 359-369.
28. Tanaka, T.; Dancheck, B.L.; Trifiletti, L.C.; Birnkrant, R.E.; Taylor, B.J.; Garfield, S.H.; Thorgeirsson, U.; De Luca, L.M., Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells. Mol. Cell Biol., 2004, 24, (9), 3972-3982.
29. Wu, R.C.; Smith, C.L.; O'Malley, B.W., Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev, 2005, 26, (3), 393-399.
30. Desvergne, B., RXR: from partnership to leadership in metabolic regulations. Vitam. Horm., 2007, 75, 1-32.
31. Kassam, A.; Miao, B.; Young, P.R.; Mukherjee, R., Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J. Biol. Chem., 2003, 278, (12), 10028-10032.
32. Zimber, A.; Gespach, C., Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med. Chem., 2008, 8, (5), 540-563.
33. Journe, F.; Laurent, G.; Chaboteaux, C.; Nonclercq, D.; Durbecq, V.; Larsimont, D.; Body, J.J., Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res. Treat., 2008, 107, (1), 49-61.
34. Arora, P.; Cuevas, B.D.; Russo, A.; Johnson, G.L.; Trejo, J., Persistent transactivation of EGFR and ErbB2/HER2 by proteaseactivated receptor-1 promotes breast carcinoma cell invasion. Oncogene, 2008, 27, (32), 4434-4445.
35. Pierce, K.L.; Tohgo, A.; Ahn, S.; Field, M.E.; Luttrell, L.M.; Lefkowitz, R.J., Epidermal growth factor (EGF) receptordependent ERK activation by G protein-coupled receptors: a coculture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J. Biol. Chem., 2001, 276, (25), 23155-23160.
36. Oyesanya, R.A.; Lee, Z.P.; Wu, J.; Chen, J.; Song, Y.; Mukherjee, A.; Dent, P.; Kordula, T.; Zhou, H.; Fang, X., Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J., 2008, 22, (8), 2639-2651.
37. Swales, K.E.; Korbonits, M.; Carpenter, R.; Walsh, D.T.; Warner, T.D.; Bishop-Bailey, D., The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res., 2006, 66, (20), 10120-10126.
38. Urquhart, B.L.; Tirona, R.G.; Kim, R.B., Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47, (5), 566-578.
39. Yasuda, H.; Hirata, S.; Inoue, K.; Mashima, H.; Ohnishi, H.; Yoshiba, M., Involvement of membrane-type bile acid receptor MBAR/ TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem. Biophys. Res. Commun., 2007, 354, (1), 154-159.
40. Rizzo, G.; Renga, B.; Mencarelli, A.; Pellicciari, R.; Fiorucci, S., Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2005, 5, (3), 289-303.
41. Hofmann, A.F.; Hagey, L.R.; Krasowski, M.D., Bile salts of vertebrates: structural variation and possible evolutionary significance. J. Lipid Res., 2010, 51, (2), 226-246.
42. Hylemon, P.B.; Zhou, H.; Pandak, W.M.; Ren, S.; Gil, G.; Dent, P., Bile acids as regulatory molecules. J. Lipid Res., 2009, 50, (8), 1509-1520.
43. Monte, M.J.; Marin, J.J.; Antelo, A.; Vazquez-Tato, J., Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol., 2009, 15, (7), 804-816.
44. Merrill, A.H., Jr.; Schmelz, E.M.; Dillehay, D.L.; Spiegel, S.; Shayman, J.A.; Schroeder, J.J.; Riley, R.T.; Voss, K.A.; Wang, E., Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol., 1997, 142, (1), 208-225.
45. Hannun, Y.A.; Loomis, C.R.; Merrill, A.H., Jr.; Bell, R.M., Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem., 1986, 261, (27), 12604-12609.
46. Merrill, A.H., Jr.; Sereni, A.M.; Stevens, V.L.; Hannun, Y.A.; Bell, R.M.; Kinkade, J.M., Jr., Inhibition of phorbol ester-dependent differentiation of human promyelocytic leukemic (HL-60) cells by sphinganine and other long-chain bases. J. Biol. Chem., 1986, 261, (27), 12610-12615.
47. Wilson, E.; Olcott, M.C.; Bell, R.M.; Merrill, A.H., Jr.; Lambeth, J.D., Inhibition of the oxidative burst in human neutrophils by sphingoid long-chain bases. Role of protein kinase C in activation of the burst. J Biol Chem, 1986, 261, (27), 12616-12623.
48. Bartke, N.; Hannun, Y.A., Bioactive sphingolipids: metabolism and function. J. Lipid Res., 2009, 50 Suppl, S91-96.
49. Futerman, A.H.; Riezman, H., The ins and outs of sphingolipid synthesis. Trends Cell Biol., 2005, 15, (6), 312-318.
50. Butler, J.; Lana, D.; Round, O.; LaMontagne, K., Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Prostaglandins Other Lipid Mediat., 2004, 73, (1-2), 29-45.
51. Hannun, Y.A.; Obeid, L.M., Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol., 2008, 9, (2), 139-150.
52. Chen, Y.; Liu, Y.; Sullards, M.C.; Merrill, A.H., Jr., An introduction to sphingolipid metabolism and analysis by new technologies. Neuromolecular Med, 2010, 12, (4), 306-319.
53. Ryland, L.K.; Fox, T.E.; Liu, X.; Loughran, T.P.; Kester, M., Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther., 2011, 11, (2), 138-149.
54. Strub, G.M.; Maceyka, M.; Hait, N.C.; Milstien, S.; Spiegel, S., Extracellular and intracellular actions of sphingosine-1-phosphate. Adv. Exp. Med. Biol., 2010, 688, 141-155.
55. Futerman, A.H.; Hannun, Y.A., The complex life of simple sphingolipids. EMBO Rep., 2004, 5, (8), 777-782.
56. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P.G.; Coso, O.A.; Gutkind, S.; Spiegel, S., Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381, (6585), 800-803.
57. Ruckhaberle, E.; Rody, A.; Engels, K.; Gaetje, R.; von Minckwitz, G.; Schiffmann, S.; Grosch, S.; Geisslinger, G.; Holtrich, U.; Karn, T.; Kaufmann, M., Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat., 2008, 112, (1), 41-52.
58. Schiffmann, S.; Sandner, J.; Birod, K.; Wobst, I.; Angioni, C.; Ruckhaberle, E.; Kaufmann, M.; Ackermann, H.; Lotsch, J.; Schmidt, H.; Geisslinger, G.; Grosch, S., Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis, 2009, 30, (5), 745-752.
59. Erez-Roman, R.; Pienik, R.; Futerman, A.H., Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression. Biochem. Biophys. Res. Commun., 2010, 391, (1), 219-223.
60. Riboni, L.; Giussani, P.; Viani, P., Sphingolipid transport. Adv Exp Med Biol, 2010, 688, 24-45.
61. Wang, T.Y.; Silvius, J.R., Different sphingolipids show differential partitioning into sphingolipid/cholesterol-rich domains in lipid bilayers. Biophys J, 2000, 79, (3), 1478-1489.
62. Ahmad, N.; Kumar, R., Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett., 2011, 300, (1), 1-9.
63. Lin, S.X.; Chen, J.; Mazumdar, M.; Poirier, D.; Wang, C.; Azzi, A.; Zhou, M., Molecular therapy of breast cancer: progress and future directions. Nat. Rev. Endocrinol., 2010, 6, (9), 485-493.
64. Margolis, R.N.; Christakos, S., The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation. An update. Ann. NY Acad. Sci., 2010, 1192, 208-214.
65. Bernstein, H.; Bernstein, C.; Payne, C.M.; Dvorakova, K.; Garewal, H., Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res., 2005, 589, (1), 47-65.
66. Raju, U.; Levitz, M.; Javitt, N.B., Bile acids in human breast cyst fluid: the identification of lithocholic acid. J. Clin. Endocrinol. Metab., 1990, 70, (4), 1030-1034.
67. Journe, F.; Durbecq, V.; Chaboteaux, C.; Rouas, G.; Laurent, G.; Nonclercq, D.; Sotiriou, C.; Body, J.J.; Larsimont, D., Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res. Treat., 2009, 115, (3), 523-535.
68. Silva, J.; Dasgupta, S.; Wang, G.; Krishnamurthy, K.; Ritter, E.; Bieberich, E., Lipids isolated from bone induce the migration of human breast cancer cells. J Lipid Res, 2006, 47, (4), 724-733.
69. Fitzgerald, M.L.; Moore, K.J.; Freeman, M.W., Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med., 2002, 80, (5), 271-281.
70. Chiang, J.Y., Bile acids: regulation of synthesis. J Lipid Res, 2009, 50, (10), 1955-1966.
71. Cai, S.Y.; He, H.; Nguyen, T.; Mennone, A.; Boyer, J.L., Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. J. Lipid Res., 2010, 51, (8), 2265-2274.
72. Catalano, S.; Malivindi, R.; Giordano, C.; Gu, G.; Panza, S.; Bonofiglio, D.; Lanzino, M.; Sisci, D.; Panno, M.L.; Ando, S., Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells. J Biol Chem, 2010, 285, (8), 5581-5593.
73. Krishnamurthy, K.; Wang, G.; Rokhfeld, D.; Bieberich, E., Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Res., 2008, 10, (6), R106.
74. Ponti, D.; Zaffaroni, N.; Capelli, C.; Daidone, M.G., Breast cancer stem cells: an overview. Eur. J. Cancer, 2006, 42, (9), 1219-1224.
75. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G., Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res, 2005, 65, (13), 5506-5511.
76. Fillmore, C.M.; Kuperwasser, C., Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 2008, 10, (2), R25.
77. Hughes, L.; Malone, C.; Chumsri, S.; Burger, A.M.; McDonnell, S., Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis, 2008, 25, (5), 549-557.
78. Morrison, B.J.; Schmidt, C.W.; Lakhani, S.R.; Reynolds, B.A.; Lopez, J.A., Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res., 2008, 10, (4), 210.
79. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Wicinski, J.; Cervera, N.; Finetti, P.; Hur, M.H.; Diebel, M.E.; Monville, F.; Dutcher, J.; Brown, M.; Viens, P.; Xerri, L.; Bertucci, F.; Stassi, G.; Dontu, G.; Birnbaum, D.; Wicha, M.S., Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res., 2009, 69, (4), 1302-1313.
80. Nakshatri, H.; Srour, E.F.; Badve, S., Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. Ther., 2009, 4, (1), 50-60.
81. Croker, A.K.; Goodale, D.; Chu, J.; Postenka, C.; Hedley, B.D.; Hess, D.A.; Allan, A.L., High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med., 2008.
82. Urizar, N.L.; Liverman, A.B.; Dodds, D.T.; Silva, F.V.; Ordentlich, P.; Yan, Y.; Gonzalez, F.J.; Heyman, R.A.; Mangelsdorf, D.J.; Moore, D.D., A natural product that lowers cholesterol as an antagonist ligand for FXR. Science, 2002, 296, (5573), 1703-1706.
83. Cui, J.; Huang, L.; Zhao, A.; Lew, J.L.; Yu, J.; Sahoo, S.; Meinke, P.T.; Royo, I.; Pelaez, F.; Wright, S.D., Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem., 2003, 278, (12), 10214-10220.
84. An, M.J.; Cheon, J.H.; Kim, S.W.; Kim, E.S.; Kim, T.I.; Kim, W.H., Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett, 2009.
85. Shishodia, S.; Harikumar, K.B.; Dass, S.; Ramawat, K.G.; Aggarwal, B.B., The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Res., 2008, 28, (6A), 3647-3664.
86. Shishodia, S.; Sethi, G.; Ahn, K.S.; Aggarwal, B.B., Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem. Pharmacol., 2007, 74, (1), 118-130.
87. Leeman-Neill, R.J.; Wheeler, S.E.; Singh, S.V.; Thomas, S.M.; Seethala, R.R.; Neill, D.B.; Panahandeh, M.C.; Hahm, E.R.; Joyce, S.C.; Sen, M.; Cai, Q.; Freilino, M.L.; Li, C.; Johnson, D.E.; Grandis, J.R., Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis, 2009, 30, (11), 1848-1856.
88. Llaverias, G.; Danilo, C.; Mercier, I.; Daumer, K.; Capozza, F.; Williams, T.M.; Sotgia, F.; Lisanti, M.P.; Frank, P.G., Role of cholesterol in the development and progression of breast cancer. Am. J. Pathol., 2011, 178, (1), 402-412.
89. Klappe, K.; Hummel, I.; Hoekstra, D.; Kok, J.W., Lipid dependence of ABC transporter localization and function. Chem. Phys. Lipids, 2009, 161, (2), 57-64.
90. Liscovitch, M.; Lavie, Y., Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem. Sci., 2000, 25, (11), 530-534.
91. Gouaze-Andersson, V.; Yu, J.Y.; Kreitenberg, A.J.; Bielawska, A.; Giuliano, A.E.; Cabot, M.C., Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta, 2007, 1771, (12), 1407-1417.
92. Ogretmen, B.; Hannun, Y.A., Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist. Updat., 2001, 4, (6), 368-377.
93. Robert, J., MS-209 Schering. Curr. Opin. Investig. Drugs, 2004, 5, (12), 1340-1347.
94. Park, M.A., The relationship between multidrug resistance and glucosylceramide levels: an opportunity for combined therapies. Cancer Biol. Ther., 2009, 8, (12), 1122-1124.
95. Gouaze, V.; Yu, J.Y.; Bleicher, R.J.; Han, T.Y.; Liu, Y.Y.; Wang, H.; Gottesman, M.M.; Bitterman, A.; Giuliano, A.E.; Cabot, M.C., Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther., 2004, 3, (5), 633-639.
96. Morjani, H.; Aouali, N.; Belhoussine, R.; Veldman, R.J.; Levade, T.; Manfait, M., Elevation of glucosylceramide in multidrugresistant cancer cells and accumulation in cytoplasmic droplets. Int. J. Cancer, 2001, 94, (2), 157-165.
97. Eckford, P.D.; Sharom, F.J., The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J., 2005, 389, (Pt 2), 517-526.
98. Shabbits, J.A.; Mayer, L.D., P-glycoprotein modulates ceramidemediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther., 2002, 1, (3), 205-213.
99. Liu, Y.Y.; Gupta, V.; Patwardhan, G.A.; Bhinge, K.; Zhao, Y.; Bao, J.; Mehendale, H.; Cabot, M.C.; Li, Y.T.; Jazwinski, S.M., Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol. Cancer, 2010, 9, 145.
100. Patwardhan, G.A.; Zhang, Q.J.; Yin, D.; Gupta, V.; Bao, J.; Senkal, C.E.; Ogretmen, B.; Cabot, M.C.; Shah, G.V.; Sylvester, P.W.; Jazwinski, S.M.; Liu, Y.Y., A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLoS One, 2009, 4, (9), e6938.
101. Sun, Y.L.; Zhou, G.Y.; Li, K.N.; Gao, P.; Zhang, Q.H.; Zhen, J.H.; Bai, Y.H.; Zhang, X.F., Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma, 2006, 53, (1), 1-8.
102. Sun, Y.; Zhang, T.; Gao, P.; Meng, B.; Gao, Y.; Wang, X.; Zhang, J.; Wang, H.; Wu, X.; Zheng, W.; Zhou, G., Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. Breast Cancer Res. Treat., 2010, 121, (3), 591-599.
103. Katayama, R.; Koike, S.; Sato, S.; Sugimoto, Y.; Tsuruo, T.; Fujita, N., Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRPmediated drug export. Cancer Sci., 2009, 100, (11), 2060-2068.
104. Saeki, T.; Nomizu, T.; Toi, M.; Ito, Y.; Noguchi, S.; Kobayashi, T.; Asaga, T.; Minami, H.; Yamamoto, N.; Aogi, K.; Ikeda, T.; Ohashi, Y.; Sato, W.; Tsuruo, T., Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J. Clin. Oncol., 2007, 25, (4), 411-417.
105. Klaassen, C.D.; Aleksunes, L.M., Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev., 2010, 62, (1), 1-96.
106. Janvilisri, T.; Venter, H.; Shahi, S.; Reuter, G.; Balakrishnan, L.; van Veen, H.W., Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J. Biol. Chem., 2003, 278, (23), 20645-20651.
107. Jung, D.; Elferink, M.G.; Stellaard, F.; Groothuis, G.M., Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int., 2007, 27, (1), 137-144.
108. Jurek, D.; Fleckl, E.; Marian, B., Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem. Toxicol., 2005, 43, (1), 87-93.
109. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B., Identification of a nuclear receptor for bile acids. Science, 1999, 284, (5418), 1362-1365.
110. Sinal, C.J.; Tohkin, M.; Miyata, M.; Ward, J.M.; Lambert, G.; Gonzalez, F.J., Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell, 2000, 102, (6), 731-744.
111. Owsley, E.; Chiang, J.Y., Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem. Biophys. Res. Commun., 2003, 304, (1), 191-195.
112. Perez-Tomas, R., Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006, 13, (16), 1859-1876.
113. Ni, Z.; Bikadi, Z.; Rosenberg, M.F.; Mao, Q., Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab., 2010, 11, (7), 603-617.
114. Doyle, L.A.; Ross, D.D., Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22, (47), 7340-7358.
115. Silva, J.; Beckedorf, A.; Bieberich, E., Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. J. Biol. Chem., 2003, 278, (28), 25376-25385.
116. Pocobelli, G.; Newcomb, P.A.; Trentham-Dietz, A.; Titus-Ernstoff, L.; Hampton, J.M.; Egan, K.M., Statin use and risk of breast cancer. Cancer, 2008, 112, (1), 27-33.
117. Kwan, M.L.; Habel, L.A.; Flick, E.D.; Quesenberry, C.P.; Caan, B., Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res. Treat., 2008, 109, (3), 573-579.
118. Kumar, A.S.; Benz, C.C.; Shim, V.; Minami, C.A.; Moore, D.H.; Esserman, L.J., Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol. Biomarkers Prev., 2008, 17, (5), 1028-1033.
119. Boudreau, D.M.; Yu, O.; Johnson, J., Statin use and cancer risk: a comprehensive review. Expert Opin. Drug Saf., 2010, 9, (4), 603-621.
120. Haukka, J.; Sankila, R.; Klaukka, T.; Lonnqvist, J.; Niskanen, L.; Tanskanen, A.; Wahlbeck, K.; Tiihonen, J., Incidence of cancer and statin usage--record linkage study. Int. J. Cancer, 2010, 126, (1), 279-284.
121. Jacobs, E.J.; Newton, C.C.; Thun, M.J.; Gapstur, S.M., Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort. Cancer Res., 2011.
122. de Moreno de LeBlanc, A.; Matar, C.; LeBlanc, N.; Perdigon, G., Effects of milk fermented by Lactobacillus helveticus R389 on a murine breast cancer model. Breast Cancer Res., 2005, 7, (4), R477-486.
123. Le, M.G.; Moulton, L.H.; Hill, C.; Kramar, A., Consumption of dairy produce and alcohol in a case-control study of breast cancer. J. Natl. Cancer Inst., 1986, 77, (3), 633-636.
124. Rachid, M.; Matar, C.; Duarte, J.; Perdigon, G., Effect of milk fermented with a Lactobacillus helveticus R389(+) proteolytic strain on the immune system and on the growth of 4T1 breast cancer cells in mice. FEMS Immunol. Med. Microbiol., 2006, 47, (2), 242-253.
125. Cohen, L.A.; Crespin, J.S.; Wolper, C.; Zang, E.A.; Pittman, B.; Zhao, Z.; Holt, P.R., Soy isoflavone intake and estrogen excretion patterns in young women: effect of probiotic administration. In Vivo, 2007, 21, (3), 507-512.
126. Park, Y.H.; Kim, J.G.; Shin, Y.W.; Kim, H.S.; Kim, Y.J.; Chun, T.; Kim, S.H.; Whang, K.Y., Effects of Lactobacillus acidophilus 43121 and a mixture of Lactobacillus casei and Bifidobacterium longum on the serum cholesterol level and fecal sterol excretion in hypercholesterolemia-induced pigs. Biosci. Biotechnol. Biochem., 2008, 72, (2), 595-600.
127. Swanton, C.; Marani, M.; Pardo, O.; Warne, P.H.; Kelly, G.; Sahai, E.; Elustondo, F.; Chang, J.; Temple, J.; Ahmed, A.A.; Brenton, J.D.; Downward, J.; Nicke, B., Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell, 2007, 11, (6), 498-512.